US20020142020A1 - Biocidal organic acid salts of a polymeric biguanide - Google Patents

Biocidal organic acid salts of a polymeric biguanide Download PDF

Info

Publication number
US20020142020A1
US20020142020A1 US09/445,765 US44576599A US2002142020A1 US 20020142020 A1 US20020142020 A1 US 20020142020A1 US 44576599 A US44576599 A US 44576599A US 2002142020 A1 US2002142020 A1 US 2002142020A1
Authority
US
United States
Prior art keywords
composition
carbon atoms
organic acid
polymeric biguanide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/445,765
Inventor
Peter Woollven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avecia Ltd
Original Assignee
Avecia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avecia Ltd filed Critical Avecia Ltd
Assigned to AVECIA LIMITED reassignment AVECIA LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOOLLVEN, PETER
Publication of US20020142020A1 publication Critical patent/US20020142020A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44Guanidine; Derivatives thereof

Definitions

  • the present invention relates to organic acid salts of polymeric biguanides, to compositions thereof, and their use as an industrial biocide or in personal care applications.
  • PHMB Poly(hexamethylenebiguanide)
  • Behenic acid is an aliphatic carboxylic acid containing a C 21 -alkyl chain and falls within the group, anionic surfactants.
  • the concentrated aqueous solution of PHMB in the form of its hydrochloride salt is clearly stated to be incompatible with anionic surfactants, alkyl sulphonates and anionic caramels as disclosed in the Product Information Notes for Vantocil IB (37-8E dated Jun. 1, 1994) and Cosmocil CQ (37-26E dated Apr. 1, 1994). Both Vantocil and Cosmocil are registered trade marks of Zeneca Specialties.
  • Bisbiguanides have also been made available commercially as water-soluble salts such as chlorhexidine (1,1′-hexamethylene bis[5-(4-chlorophenyl)-biguanide]digluconate) and alexidine (1,1′-hexamethylene bis [5-(4-(2-ethylhexyl)phenyl)-biguanide]-diacetate).
  • water-soluble salts and PHMB hydrochloride are not particularly suited to provide a solution of the polymeric biguanide in organic liquids, especially non-polar organic liquids.
  • PHMB in the form of its salt of an organic acid containing from 4 to 30 carbon atoms exhibits high antimicrobial, especially antibacterial activity, and that such salts exhibit increased solubility in organic media, especially organic liquids.
  • composition comprising a carrier and a polymeric biguanide in the form of its salt with an organic acid containing from 4 to 30 carbon atoms, including mixtures thereof.
  • the polymeric biguanide contains at least one biguanide unit of Formula 1.
  • the polymeric biguanide contains at least two biguanide units of Formula 1 which are linked by a bridging group which contains at least one methylene group.
  • the bridging group may include a polymethylene chain which may optionally be interrupted by hetero atoms such as oxygen, sulphur or nitrogen.
  • the bridging group may include one or more cyclic nuclei which may be saturated or unsaturated.
  • the bridging group is such that there are at least three, and especially at least four, carbon atoms directly interposed between two adjacent biguanide units of Formula 1.
  • the polymeric biguanide may be terminated by any suitable group which may be a hydrocarbyl or substituted hydrocarbyl group or an amine or a group
  • the terminating group is a hydrocarbyl group, it may be alkyl, cycloalkyl or aralkyl.
  • the substituent may be any substituent that does not exhibit an undesirable adverse effect on the microbiological properties of the polymeric biguanide.
  • substituents or substituted hydrocarbyl groups are aryloxy, alkoxy, acyl, acyloxy, halogen and nitrile.
  • the polymeric biguanide contains two biguanide groups of Formula 1
  • the two biguanide units are preferably linked by a polymethylene group, especially a hexamethylene group.
  • the terminating groups in such polymeric biguanides are preferably 4-chlorophenyl or 2-ethylhexyl. Examples of such compounds are represented by Formulae 2 and 3 in their free base form
  • the polymeric biguanide preferably contains more than two biguanide units of Formula 1 and preferably is a linear polymeric biguanide which has a recurring polymeric unit represented by Formula 4
  • X and Y may be the same or different and represent bridging groups in which, together, the total number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is not less than 9 and not greater than 17.
  • the bridging groups X and Y may consist of a polymethylene chain, optionally interrupted by a heteroatom such as oxygen, sulphur or nitrogen.
  • X and Y may also incorporate a cyclic nucleus which may be saturated or unsaturated, wherein the number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is taken as including that segment of the cyclic group, or groups, which is the shortest.
  • the preferred polymeric biguanide for use in the present invention is poly(hexamethylenebiguanide), in which both X and Y in Formula 4 are the group —(CH 2 ) 6 +
  • the polymeric biguanides of Formula 4 are typically obtained as mixtures of polymers in which the polymer chains are of different lengths. Preferably, the number of individual biguanide units
  • [0018] is, together, from 3 to about 80.
  • n is from 4 to 40 and especially from 4 to 15. It is particularly preferred that the average value of n in the mixture is 12. Preferably, the average molecular weight of the polymer mixture is from 1100 to 3300.
  • the organic acid which forms the salt with the polymeric biguanide may contain a phosphonic, phosphoric, sulphonic or sulphate group but preferably contains a carboxylic acid group.
  • the organic acid may be aromatic but is preferably aliphatic, including alicyclic.
  • the aliphatic chain of the organic acid may be linear or branched, saturated or unsaturated, including mixtures thereof.
  • the aliphatic chain is linear and it is also preferred that the organic acid is an aliphatic carboxylic acid.
  • the organic acid contains not less than eight, more preferably not less than ten and especially not less than twelve carbon atoms excluding the acid group.
  • the organic acid contains not greater than 24, more preferably not greater than 20 and especially not greater than 18 carbon atoms excluding the acid group.
  • the organic acid may contain more than one acid group but it is preferred that only one such group is present.
  • the organic acid may be substituted by a halogen or particularly hydroxy group. It is, however, preferred that the organic acid is free from substituents.
  • aliphatic carboxylic acids are available commercially as mixtures such as those obtained from animal fats and vegetable oils and these contain both saturated and unsaturated aliphatic chains. These have also been found useful, especially the C 14-18 -alkyl carboxylic acids and their fully saturated or hydrogenated analogues.
  • Examples of optionally substituted carboxylic acids are valeric, hexanoic, octanoic, 2-octenoic, lauric, 5-dodecenoic, myristic, pentadecanoic, palmitic, oleic, stearic, eicosanoic, heptadecanoic, palmitoleic, ricinoleic, 1 2-hydroxystearic, 16-hydroxyhexadecanoic, 2-hydroxycaproic, 1 2-hydroxydodecanoic, 5-hydroxydodecanoic, 5-hydroxydecanoic, 4-hydroxydecanoic, dodecanedioic, undecanedioic, sebacic, benzoic, hydroxbenzoic and teraphthalic acids.
  • the carrier may be a solid but is preferably a liquid.
  • the liquid may be water whereby the composition containing the organic acid is a dispersion or emulsion.
  • the aqueous composition also contains a surfactant, particularly a non-ionic surfactant such as a polyalkylene oxide and especially an ethoxylate.
  • the aqueous composition may also contain other adjuvents which help distribute the polymeric biguanide salt uniformly throughout the composition. Examples of such adjuvants are compounds which provide structure to the water to inhibit sedimentation such as alginates and gums, particularly Xanthan gum.
  • the carrier is a liquid it is preferably a polar organic liquid, a substantially non-polar organic liquid or a halogenated hydrocarbon.
  • polar in relation to the organic liquid is meant an organic liquid or resin capable of forming moderate to strong bonds as described in the article entitled “A Three Dimensional Approach to Solubility” by Crowley et al in Journal of Paint Technology, Vol. 38, 1966, at page 269.
  • Such organic liquids generally have a hydrogen bonding number of 5 or more as defined in the abovementioned article.
  • Suitable polar organic liquids are amines, ethers, especially lower alkyl ethers, organic acids, esters, ketones, glycols, alcohols and amides. Numerous specific examples of such moderately strongly hydrogen bonding liquids are given in the book entitled “Compatibility and Solubility” by Ibert Mellan (published in 1968 by Noyes Development Corporation) in Table 2.14 on pages 3940 and these liquids all fall within the scope of the term polar organic liquid as used herein.
  • Preferred polar organic liquids are dialkyl ketones, alkyl esters of alkane carboxylic acids and alkanols, especially such liquids containing up to, and including, a total of 6 carbon atoms.
  • dialkyl and cycloalkyl ketones such as acetone, methyl ethyl ketone, diethyl ketone, di-isopropyl ketone, methyl isobutyl ketone, di-isobutyl ketone, methyl isoamyl ketone, methyl n-amyl ketone and cyclohexanone
  • alkyl esters such as methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, ethyl formate, methyl propionate, methoxy propylacetate and ethyl butyrate
  • the substantially non-polar, organic liquids which may be used, either alone or in admixture with the aforementioned polar liquids, are aliphatic and aromatic hydrocarbons, such as toluene and xylene, and halogenated aliphatic and aromatic hydrocarbons, such as trichloro-ethylene, perchloroethylene and chlorobenzene.
  • the organic acid salt of the polymeric biguanide may be made by any method known to the art but is preferably made by precipitation of the biguanide from aqueous solution by addition of the organic acid under alkaline conditions.
  • the organic acid salts of the biguanide may be further purified by dissolution in a suitable organic liquid which is preferably immiscible with water and washing the organic phase with water to remove any residual water soluble salts.
  • the amount of polymeric biguanide in the composition may vary between wide limits depending on its end usage. Thus, where the composition is used to confer antimicrobial protection to a medium which is to be protected against microbiological spoilage the amount of polymeric biguanide may be just sufficient to provide such protection.
  • the amount of biguanide is not less than 1 ppm, more preferably not less than 10 ppm and especially not less than 20 ppm. It will be appreciated that where the composition containing the salt of the polymeric biguanide is to be transported in bulk the amount of the polymeric biguanide salt is as high as possible provided that the biguanide salt remains uniformly distributed throughout the composition.
  • the amount of polymeric biguanide salt in the composition is not greater than 30%, more preferably not greater than 25% and especially not greater than 20% based on the total weight of the composition.
  • polymeric biguanides in the form of a salt with an organic acid containing from 4 to 30 carbon atoms are novel.
  • a polymeric biguanide in the form of a salt with an aliphatic carboxylic acid containing from 4 to 20 carbon atoms, particularly from 10 to 20 carbon atoms and especially from 12 to 18 carbon atoms excluding the —COOH group, optionally substituted by hydroxy is provided.
  • the aliphatic carboxylic acid is free from substituents.
  • the aliphatic carboxylic acid may be linear or branched, saturated or unsaturated, including mixtures thereof. It is preferred that the aliphatic carboxylic acid is linear and saturated.
  • the polymeric biguanide is PHMB.
  • the organic acid salts of the polymeric biguanide exhibit antimicrobial, especially antibacterial, activity. Consequently, the polymeric biguanide salts or compositions containing the polymeric biguanide salts may be used to protect various media from microbiological growth.
  • the medium may be an industrial medium such as a cooling water tower liquid, paper mill liquor, metal working fluid, geological drilling lubricant, polymer emulsion, surface coating composition such as paint, varnish or lacquer.
  • the medium to be protected can be a solid such as wood or leather and particularly solid surfaces in the health-care or food preparation industries.
  • the solid may also be a textile material such as cellulose, including its blends with synthetic polymers and also non-woven materials such as those used in disposable items such as nappies, incontinence pads and feminine hygiene packs.
  • the polymeric biguanide salt may be applied by any method known to the art such as spraying, dipping or coating with a composition containing the polymeric biguanide salt.
  • the amount of polymeric biguanide salt which is applied to the medium to be protected from microbiological growth may be just sufficient to inhibit such growth or it may be in -excess of such amount.
  • the amount of polymeric biguanide salt which is applied to such medium is not greater than 2% and more preferably not greater than 1% by weight of the medium.
  • adequate protection is provided by from 1 ppm to 500 ppm, particularly 10 to 200 ppm and especially 10 to 100 ppm of the polymeric biguanide salt relating to the medium.
  • the product was obtained as a paste containing 11.0 Kgm PHMB stearate (50% theory).
  • the PHMB stearate salt exhibited similar microbiological activity to the hydrochloride salt when allowance is made for the different molecular weights.
  • Palmitic acid (1.35 parts ex Aldrich) were dissolved in water (15 ml) by heating to 60° C. and adjusting the pH value to between 9 and 10 by adding caustic soda.
  • PHMB hydrochloride (1 part as 20% solution, Cosmocil CQ ex Zeneca) was added and the reactants stirred at 80° C. for 2 hours. The reaction mass was then cooled to 20° C. whereupon the PHMB palmitate separated as a clear gum (1.86 parts).
  • Example 2 was repeated except replacing the palmitic acid with an equivalent amount of lauric acid and octanoic acid, respectively.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A composition comprising a carrier and a polymeric biguanide in the form of its salt with an organic acid containing from 4 to 30 carbon atoms such as poly (hexamethylenebiguanide) stearate.

Description

  • The present invention relates to organic acid salts of polymeric biguanides, to compositions thereof, and their use as an industrial biocide or in personal care applications. [0001]
  • Poly(hexamethylenebiguanide) (hereinafter PHMB) has found many uses as a broad spectrum bactericide in both industrial and personal care applications and is commercially available as an aqueous concentrate of its hydrochloride salt. For most applications, the use of PHMB in the form of its hydrochloride salt is eminently suitable. However, there exist some applications where the presence of chloride ion can cause undesirable side effects such as corrosion of metal surfaces. GB 1,464,005 discloses that other salts of PHMB may be used as molluscicides, such as sulphate, acetate, gluconate and behenate. However, no microbiological data is recorded for such salts. Behenic acid is an aliphatic carboxylic acid containing a C[0002] 21-alkyl chain and falls within the group, anionic surfactants. The concentrated aqueous solution of PHMB in the form of its hydrochloride salt is clearly stated to be incompatible with anionic surfactants, alkyl sulphonates and anionic caramels as disclosed in the Product Information Notes for Vantocil IB (37-8E dated Jun. 1, 1994) and Cosmocil CQ (37-26E dated Apr. 1, 1994). Both Vantocil and Cosmocil are registered trade marks of Zeneca Specialties.
  • Bisbiguanides have also been made available commercially as water-soluble salts such as chlorhexidine (1,1′-hexamethylene bis[5-(4-chlorophenyl)-biguanide]digluconate) and alexidine (1,1′-hexamethylene bis [5-(4-(2-ethylhexyl)phenyl)-biguanide]-diacetate). These water-soluble salts and PHMB hydrochloride are not particularly suited to provide a solution of the polymeric biguanide in organic liquids, especially non-polar organic liquids. [0003]
  • It has now been found that PHMB in the form of its salt of an organic acid containing from 4 to 30 carbon atoms exhibits high antimicrobial, especially antibacterial activity, and that such salts exhibit increased solubility in organic media, especially organic liquids. [0004]
  • According to the present invention there is provided a composition comprising a carrier and a polymeric biguanide in the form of its salt with an organic acid containing from 4 to 30 carbon atoms, including mixtures thereof. [0005]
  • The polymeric biguanide contains at least one biguanide unit of Formula 1. [0006]
    Figure US20020142020A1-20021003-C00001
  • Preferably, the polymeric biguanide contains at least two biguanide units of Formula 1 which are linked by a bridging group which contains at least one methylene group. The bridging group may include a polymethylene chain which may optionally be interrupted by hetero atoms such as oxygen, sulphur or nitrogen. The bridging group may include one or more cyclic nuclei which may be saturated or unsaturated. Preferably, the bridging group is such that there are at least three, and especially at least four, carbon atoms directly interposed between two adjacent biguanide units of Formula 1. Preferably, there are not greater than ten and especially not greater than eight carbon atoms interposed between two adjacent biguanide units of Formula 1. [0007]
  • The polymeric biguanide may be terminated by any suitable group which may be a hydrocarbyl or substituted hydrocarbyl group or an amine or a group [0008]
    Figure US20020142020A1-20021003-C00002
  • When the terminating group is a hydrocarbyl group, it may be alkyl, cycloalkyl or aralkyl. [0009]
  • When the terminating group is a substituted hydrocarbyl group, the substituent may be any substituent that does not exhibit an undesirable adverse effect on the microbiological properties of the polymeric biguanide. Examples of such substituents or substituted hydrocarbyl groups are aryloxy, alkoxy, acyl, acyloxy, halogen and nitrile. [0010]
  • When the polymeric biguanide contains two biguanide groups of Formula 1, the two biguanide units are preferably linked by a polymethylene group, especially a hexamethylene group. The terminating groups in such polymeric biguanides are preferably 4-chlorophenyl or 2-ethylhexyl. Examples of such compounds are represented by Formulae 2 and 3 in their free base form [0011]
    Figure US20020142020A1-20021003-C00003
  • The polymeric biguanide preferably contains more than two biguanide units of Formula 1 and preferably is a linear polymeric biguanide which has a recurring polymeric unit represented by Formula 4 [0012]
    Figure US20020142020A1-20021003-C00004
  • wherein X and Y may be the same or different and represent bridging groups in which, together, the total number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is not less than 9 and not greater than 17. [0013]
  • The bridging groups X and Y may consist of a polymethylene chain, optionally interrupted by a heteroatom such as oxygen, sulphur or nitrogen. X and Y may also incorporate a cyclic nucleus which may be saturated or unsaturated, wherein the number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is taken as including that segment of the cyclic group, or groups, which is the shortest. Thus, the number of carbon atoms directly interposed between the nitrogen atoms in the group [0014]
    Figure US20020142020A1-20021003-C00005
  • is 4 and not 8. [0015]
  • The preferred polymeric biguanide for use in the present invention is poly(hexamethylenebiguanide), in which both X and Y in Formula 4 are the group —(CH[0016] 2)6+
  • The polymeric biguanides of Formula 4 are typically obtained as mixtures of polymers in which the polymer chains are of different lengths. Preferably, the number of individual biguanide units [0017]
    Figure US20020142020A1-20021003-C00006
  • is, together, from 3 to about 80. [0018]
  • In the case of the preferred poly(hexamethylenebiguanide) it is a mixture represented by the compounds of Formula 5 in the free-base form. [0019]
    Figure US20020142020A1-20021003-C00007
  • wherein the value of n is from 4 to 40 and especially from 4 to 15. It is particularly preferred that the average value of n in the mixture is 12. Preferably, the average molecular weight of the polymer mixture is from 1100 to 3300. [0020]
  • The organic acid which forms the salt with the polymeric biguanide may contain a phosphonic, phosphoric, sulphonic or sulphate group but preferably contains a carboxylic acid group. The organic acid may be aromatic but is preferably aliphatic, including alicyclic. When the organic acid is aliphatic, the aliphatic chain of the organic acid may be linear or branched, saturated or unsaturated, including mixtures thereof. Preferably, the aliphatic chain is linear and it is also preferred that the organic acid is an aliphatic carboxylic acid. [0021]
  • It is preferred that the organic acid contains not less than eight, more preferably not less than ten and especially not less than twelve carbon atoms excluding the acid group. Preferably, the organic acid contains not greater than 24, more preferably not greater than 20 and especially not greater than 18 carbon atoms excluding the acid group. [0022]
  • The organic acid may contain more than one acid group but it is preferred that only one such group is present. [0023]
  • The organic acid may be substituted by a halogen or particularly hydroxy group. It is, however, preferred that the organic acid is free from substituents. [0024]
  • Some aliphatic carboxylic acids are available commercially as mixtures such as those obtained from animal fats and vegetable oils and these contain both saturated and unsaturated aliphatic chains. These have also been found useful, especially the C[0025] 14-18-alkyl carboxylic acids and their fully saturated or hydrogenated analogues.
  • Examples of optionally substituted carboxylic acids are valeric, hexanoic, octanoic, 2-octenoic, lauric, 5-dodecenoic, myristic, pentadecanoic, palmitic, oleic, stearic, eicosanoic, heptadecanoic, palmitoleic, ricinoleic, 1 2-hydroxystearic, 16-hydroxyhexadecanoic, 2-hydroxycaproic, 1 2-hydroxydodecanoic, 5-hydroxydodecanoic, 5-hydroxydecanoic, 4-hydroxydecanoic, dodecanedioic, undecanedioic, sebacic, benzoic, hydroxbenzoic and teraphthalic acids. [0026]
  • Particularly useful effects have been obtained when the aliphatic carboxylic acid is stearic acid and the polymeric biguanide is PHMB. [0027]
  • The carrier may be a solid but is preferably a liquid. [0028]
  • The liquid may be water whereby the composition containing the organic acid is a dispersion or emulsion. Preferably, the aqueous composition also contains a surfactant, particularly a non-ionic surfactant such as a polyalkylene oxide and especially an ethoxylate. The aqueous composition may also contain other adjuvents which help distribute the polymeric biguanide salt uniformly throughout the composition. Examples of such adjuvants are compounds which provide structure to the water to inhibit sedimentation such as alginates and gums, particularly Xanthan gum. [0029]
  • When the carrier is a liquid it is preferably a polar organic liquid, a substantially non-polar organic liquid or a halogenated hydrocarbon. By the term “polar” in relation to the organic liquid is meant an organic liquid or resin capable of forming moderate to strong bonds as described in the article entitled “A Three Dimensional Approach to Solubility” by Crowley et al in Journal of Paint Technology, Vol. 38, 1966, at page 269. Such organic liquids generally have a hydrogen bonding number of 5 or more as defined in the abovementioned article. [0030]
  • Examples of suitable polar organic liquids are amines, ethers, especially lower alkyl ethers, organic acids, esters, ketones, glycols, alcohols and amides. Numerous specific examples of such moderately strongly hydrogen bonding liquids are given in the book entitled “Compatibility and Solubility” by Ibert Mellan (published in 1968 by Noyes Development Corporation) in Table 2.14 on pages 3940 and these liquids all fall within the scope of the term polar organic liquid as used herein. [0031]
  • Preferred polar organic liquids are dialkyl ketones, alkyl esters of alkane carboxylic acids and alkanols, especially such liquids containing up to, and including, a total of 6 carbon atoms. As examples of the preferred and especially preferred liquids there may be mentioned dialkyl and cycloalkyl ketones, such as acetone, methyl ethyl ketone, diethyl ketone, di-isopropyl ketone, methyl isobutyl ketone, di-isobutyl ketone, methyl isoamyl ketone, methyl n-amyl ketone and cyclohexanone; alkyl esters such as methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, ethyl formate, methyl propionate, methoxy propylacetate and ethyl butyrate; glycols and glycol esters and ethers, such as ethylene glycol, 2-ethoxyethanol, 3-methoxypropylpropanol, 3-ethoxypropylpropanol, 2-butoxyethyl acetate, 3-methoxypropyl acetate, 3-ethoxypropyl acetate and 2-ethoxyethyl acetate; alkanols such as methanol, ethanol, n-propanol, isopropanol, n-butanol and isobutanol and dialkyl and cyclic ethers such as diethyl ether and tetrahydrofuran. [0032]
  • The substantially non-polar, organic liquids which may be used, either alone or in admixture with the aforementioned polar liquids, are aliphatic and aromatic hydrocarbons, such as toluene and xylene, and halogenated aliphatic and aromatic hydrocarbons, such as trichloro-ethylene, perchloroethylene and chlorobenzene. [0033]
  • The organic acid salt of the polymeric biguanide may be made by any method known to the art but is preferably made by precipitation of the biguanide from aqueous solution by addition of the organic acid under alkaline conditions. The organic acid salts of the biguanide may be further purified by dissolution in a suitable organic liquid which is preferably immiscible with water and washing the organic phase with water to remove any residual water soluble salts. [0034]
  • The amount of polymeric biguanide in the composition may vary between wide limits depending on its end usage. Thus, where the composition is used to confer antimicrobial protection to a medium which is to be protected against microbiological spoilage the amount of polymeric biguanide may be just sufficient to provide such protection. Preferably the amount of biguanide is not less than 1 ppm, more preferably not less than 10 ppm and especially not less than 20 ppm. It will be appreciated that where the composition containing the salt of the polymeric biguanide is to be transported in bulk the amount of the polymeric biguanide salt is as high as possible provided that the biguanide salt remains uniformly distributed throughout the composition. Preferably, the amount of polymeric biguanide salt in the composition is not greater than 30%, more preferably not greater than 25% and especially not greater than 20% based on the total weight of the composition. [0035]
  • Some of the polymeric biguanides in the form of a salt with an organic acid containing from 4 to 30 carbon atoms are novel. Thus, according to a further aspect of the invention there is provided a polymeric biguanide in the form of a salt with an aliphatic carboxylic acid containing from 4 to 20 carbon atoms, particularly from 10 to 20 carbon atoms and especially from 12 to 18 carbon atoms excluding the —COOH group, optionally substituted by hydroxy. [0036]
  • It is particularly preferred that the aliphatic carboxylic acid is free from substituents. [0037]
  • The aliphatic carboxylic acid may be linear or branched, saturated or unsaturated, including mixtures thereof. It is preferred that the aliphatic carboxylic acid is linear and saturated. [0038]
  • It is especially preferred that the polymeric biguanide is PHMB. [0039]
  • As noted hereinbefore, the organic acid salts of the polymeric biguanide exhibit antimicrobial, especially antibacterial, activity. Consequently, the polymeric biguanide salts or compositions containing the polymeric biguanide salts may be used to protect various media from microbiological growth. [0040]
  • According to a still further aspect of the invention there is provided a method for inhibiting microbiological growth on, or in a medium which comprises treating the medium with a polymeric biguanide in the form of its salt with an organic acid containing from 4 to 30 carbon atoms. The polymeric biguanide salt can be used in any conditions in which micro-organisms grow and cause problems. Thus, the medium may be an industrial medium such as a cooling water tower liquid, paper mill liquor, metal working fluid, geological drilling lubricant, polymer emulsion, surface coating composition such as paint, varnish or lacquer. The medium to be protected can be a solid such as wood or leather and particularly solid surfaces in the health-care or food preparation industries. The solid may also be a textile material such as cellulose, including its blends with synthetic polymers and also non-woven materials such as those used in disposable items such as nappies, incontinence pads and feminine hygiene packs. [0041]
  • Where the medium to be protected is a solid, the polymeric biguanide salt may be applied by any method known to the art such as spraying, dipping or coating with a composition containing the polymeric biguanide salt. [0042]
  • As noted hereinbefore, the amount of polymeric biguanide salt which is applied to the medium to be protected from microbiological growth may be just sufficient to inhibit such growth or it may be in -excess of such amount. Preferably, the amount of polymeric biguanide salt which is applied to such medium is not greater than 2% and more preferably not greater than 1% by weight of the medium. Generally, adequate protection is provided by from 1 ppm to 500 ppm, particularly 10 to 200 ppm and especially 10 to 100 ppm of the polymeric biguanide salt relating to the medium. [0043]
  • The invention is illustrated by the following examples wherein all parts and percentages are references to weight unless indicated to the contrary.[0044]
  • EXAMPLE 1 Preparation of Stearate Salt of PHMB
  • Water (150 litres) was added to a reactor vessel followed by stearic acid (14.8 Kgm, 0.047M). Sodium hydroxide flake (1.88 Kgm, 0.047M) was added with stirring, giving a pH value in the range 9.0 to 10.0. PHMB hydrochloride (50 litres as 20% aqueous solution, 0.047M, Vantocil IB ex. Zeneca) was added and the reactants stirred at 80° C. for 2 hours. After cooling, the PHMB stearate salt was separated on a slurry filter, washed with water and dried. [0045]
  • The product was obtained as a paste containing 11.0 Kgm PHMB stearate (50% theory). [0046]
  • The PHMB stearate salt exhibited similar microbiological activity to the hydrochloride salt when allowance is made for the different molecular weights. [0047]
  • EXAMPLE 2
  • Palmitic acid (1.35 parts ex Aldrich) were dissolved in water (15 ml) by heating to 60° C. and adjusting the pH value to between 9 and 10 by adding caustic soda. PHMB hydrochloride (1 part as 20% solution, Cosmocil CQ ex Zeneca) was added and the reactants stirred at 80° C. for 2 hours. The reaction mass was then cooled to 20° C. whereupon the PHMB palmitate separated as a clear gum (1.86 parts). [0048]
  • EXAMPLES 3 and 4
  • Example 2 was repeated except replacing the palmitic acid with an equivalent amount of lauric acid and octanoic acid, respectively. [0049]
  • EXAMPLES 5 to 11
  • The MIC values for the different salts of poly(hexamethylene biguanide) were determined by dissolving the salts in methanol/dimethylformamide (1:6). The results are given in Table 1 below and show that the different salts exhibit similar antimicrobial activity against yeast and bacteria. [0050]
    TABLE 1
    Example Anion C. albicans E.coli St. aureus
    5 stearate 100 2.3 3.1
    6 palmitate 150 4.7 4.7
    7 octanoate >150 0.8 2.3
    8 laurate >150 1.2 1.2
    9 chloride (D) >150 0.8 1.2
    10 chloride (W) >150 0.4 1.6
    11 stearate (M) >150 2.3 3.1

Claims (14)

1. A composition comprising a carrier and a linear polymeric biguanide which has a recurring polymeric unit represented by formula 4 in the form of its salt with an organic acid containing from 4 to 30 carbon atoms which is optionally substituted by a halogen or a hydroxy group, including salts thereof
Figure US20020142020A1-20021003-C00008
wherein x and y may be the same or different and represent bridging groups in which together, the total number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by x and y is not less than 9 and not greater than 17.
2. A composition as claimed in claim 1 wherein both X and Y is the group —(CH2)6—.
3. A composition as claimed in either claim 1 or claim 2 wherein the polymeric biguanide is a mixture represented by the compounds of Formula 5 in the free-base form
Figure US20020142020A1-20021003-C00009
wherein n is from 4 to 40.
4. A composition as claimed in any one of claims 1 to 3 wherein the organic acid contains a carboxylic acid group.
5. A composition as claimed in any one of claims 1 to 4 wherein the organic acid contains not less than 8 carbon atoms.
6. A composition as claimed in any one of claims 1 to 5 wherein the organic acid contains from 12 to 18 carbon atoms.
7. A composition as claimed in any one of claims 1 to 6 wherein the organic acid is free from substituents.
8. A composition as claimed in any one of claims 1 to 4 wherein the organic acid is selected from valeric, hexanoic, octanoic, 2-octenoic, lauric, 5-dodecenoic, myristic, oentadecanoic, palmitic, oleic, stearic, eicosanoic, heptadecanoic, palmitoleic, ricinoleic 12-hydroxystearic, 16-hydroxyhexadecanoic, 2-hydroxycaproic, 12-hydroxydodecanoic, 5-hydroxydodecanoic, 5-hydroxydecanoic, 4-hydroxydecanoic, dodecanedioic, undecanedioic, sebacic, benzoic, hydroxbenzoic and teraphthalic acids.
9. A composition as claimed in any one of claims 1 to 8 wherein the carrier is a polar organic liquid, a substantially non-polar organic liquid or a halogenated hydrocarbon.
10. A composition as claimed in claim 9 wherein the polar organic liquid is an alkanol.
11. A linear polymeric biguanide which has a recurring polymeric unit represented by formula 4 in the form of its salt with an unsubstituted aliphatic carboxylic acid containing from 4 to 20 carbon atoms excluding the acid group
Figure US20020142020A1-20021003-C00010
wherein X and Y may be the same or different and represent bridging groups in which together, the total number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is not less than 9 and not greater than 17.
12. The salt of a polymeric biguanide as claimed in claim 11 wherein the polymeric biguanide is a mixture represented by the compounds of Formula 5 in the free-base form
Figure US20020142020A1-20021003-C00011
wherein n is from 4 to 40.
13. The salt of a polymeric biguanide as claimed in either claim 11 or claim 12 wherein the aliphatic acid is stearic acid.
14. A method for inhibiting microbiological growth on, or in, a medium which comprises treating the medium with a linear polymeric biguanide which has a recurring polymeric unit represented by formula 4 in the form of its salt with an organic acid containing from 4 to 30 carbon atoms which is optionally substituted by a halogen or a hydroxy group, including salts thereof
Figure US20020142020A1-20021003-C00012
wherein X and Y may be the same or different and represent bridging groups in which together, the total number of carbon atoms directly interposed between the pairs of nitrogen atoms linked by X and Y is not less than 9 and not greater than 17.
US09/445,765 1997-06-13 1998-06-05 Biocidal organic acid salts of a polymeric biguanide Abandoned US20020142020A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712317.8A GB9712317D0 (en) 1997-06-13 1997-06-13 Composition, compound and use
GB9712317.8 1997-06-13

Publications (1)

Publication Number Publication Date
US20020142020A1 true US20020142020A1 (en) 2002-10-03

Family

ID=10814094

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/445,765 Abandoned US20020142020A1 (en) 1997-06-13 1998-06-05 Biocidal organic acid salts of a polymeric biguanide
US09/094,324 Expired - Lifetime US6509022B2 (en) 1997-06-13 1998-06-09 Composition for use in personal care comprising organic acid salts of polymeric biguanidines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/094,324 Expired - Lifetime US6509022B2 (en) 1997-06-13 1998-06-09 Composition for use in personal care comprising organic acid salts of polymeric biguanidines

Country Status (22)

Country Link
US (2) US20020142020A1 (en)
EP (2) EP0987947B1 (en)
JP (2) JP4308331B2 (en)
KR (1) KR20010013704A (en)
CN (2) CN100577142C (en)
AR (2) AR012965A1 (en)
AT (1) ATE227932T1 (en)
AU (2) AU742600B2 (en)
BR (2) BR9810435B1 (en)
CA (2) CA2295012A1 (en)
DE (2) DE69817564T2 (en)
ES (1) ES2205509T3 (en)
GB (1) GB9712317D0 (en)
HU (1) HUP0003065A3 (en)
ID (1) ID24652A (en)
IN (1) IN190655B (en)
NO (1) NO996042L (en)
NZ (1) NZ501740A (en)
PL (1) PL188771B1 (en)
RU (1) RU2209620C2 (en)
WO (2) WO1998056252A1 (en)
ZA (2) ZA985030B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075131A1 (en) * 2008-09-19 2010-03-25 Etzel Mark R Ligand Graft Functionalized Substrates
WO2011131773A1 (en) 2010-04-23 2011-10-27 Centre National De La Recherche Scientifique (C.N.R.S) Novel antimicrobial composition, use and preparation thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147925A1 (en) * 1998-09-11 2003-08-07 Samuel P. Sawan Topical dermal antimicrobial compositions, methods for generating same, and monitoring methods utilizing same
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
FR2827507B1 (en) * 2001-07-18 2005-07-01 Oreal POLYGUANIDINE DERIVATIVE COMPOUND AND USE OF SUCH A COMPOUND FOR THE PROTECTION AND / OR CARE OF KERATIN FIBERS
FR2830442B1 (en) * 2001-10-09 2004-02-06 Oreal USE OF A POLYGUANIDINE COMPOUND FOR TREATMENT OR HAIR SHAPING, ESPECIALLY STRAIGHTENING OR PERMANENT
ATE364684T1 (en) 2001-10-09 2007-07-15 Procter & Gamble MOISTIFIED WIPE CONTAINING POLYMERIC BIGUANIDE COMPOUNDS FOR THE TREATMENT OF SURFACES
FR2841778B1 (en) * 2002-07-05 2004-10-01 Oreal USE OF A POLYGUANIDINE-DERIVED COMPOUND IN A COLOR TREATMENT
US8795638B1 (en) * 2003-08-26 2014-08-05 Nevada Naturals Inc. Compositions for dental care
FR2860158A1 (en) * 2003-09-30 2005-04-01 Oreal Foaming, cleaning composition containing a polyguanidine derivative, useful as cosmetic cleanser and for treating greasy skin, also contains at least one lathering surfactant
RU2256439C1 (en) * 2004-04-08 2005-07-20 Генкин Дмитрий Дмитриевич Formulation for facial skin washing
DE102004037598A1 (en) * 2004-08-03 2006-02-23 Prontomed Gmbh Medium, useful as mouth and throat rinsing solution or mouth spray, comprises microbicide aqueous solution comprising a linear biguanide polymer and/or water-soluble salt of microbicide in combination with a sweetener
US20060272107A1 (en) * 2005-05-17 2006-12-07 Gerard Malle Hair relaxing composition comprising at least one non-hydroxide polyguanidine
US20060269498A1 (en) * 2005-05-17 2006-11-30 Gerard Malle Hair shaping composition comprising at least one polyguanidine other than hydroxide
FR2885902B1 (en) * 2005-05-17 2008-05-09 Oreal HAIR REMOVAL COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE MULTIGUANIDINE
FR2885800B1 (en) * 2005-05-17 2008-05-09 Oreal HAIR FORMING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE MULTIGUANIDINE
EP1924298B1 (en) * 2005-09-15 2010-07-14 Aesculap AG Biocompatible antimicrobial suture material
KR20090075701A (en) * 2006-10-27 2009-07-08 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Antimicrobial compositions
JP2011507978A (en) * 2007-12-31 2011-03-10 スリーエム イノベイティブ プロパティズ カンパニー Antibacterial composition
WO2009097467A2 (en) * 2008-01-29 2009-08-06 Tetsuo Nakatsu A functional material and delivery gel composition and method for manufacturing the same
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
PL2524705T3 (en) * 2011-05-19 2014-12-31 Lohmann & Rauscher Gmbh & Co Kg Sterilized wound dressing comprising a triblock-elastomeric component and hydrophobic polymeric Biguanid
US10289412B2 (en) * 2012-02-09 2019-05-14 Qualcomm Incorporated Floating point constant generation instruction
WO2013121407A1 (en) * 2012-02-17 2013-08-22 Budhi Haryanto The composition of malodor removing aerosol for daily worn objects or items
CN105315459B (en) * 2014-10-29 2017-09-26 吉林云飞医药有限公司 A kind of preparation method of polyadipate base guanidine hydrochloride
CN109890354B (en) 2016-10-24 2020-10-02 高露洁-棕榄公司 Oral care compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843676A (en) * 1957-12-31 1960-08-10 Ici Ltd New biguanide salts
BE698595A (en) * 1966-05-23 1967-11-17
GB1434040A (en) * 1973-08-06 1976-04-28 Ici Ltd Process for combating fungi and bacteria
GB1464005A (en) * 1974-04-22 1977-02-09 Ici Ltd Method for the destruction of aquatic molluscs
LU74539A1 (en) * 1976-03-12 1977-09-27
US4478821A (en) * 1982-01-26 1984-10-23 The Gillette Company Inhibition of body odor
JP2544388B2 (en) * 1986-09-04 1996-10-16 株式会社 上野製薬応用研究所 Virus inactivating agent
AU633499B2 (en) * 1988-06-30 1993-02-04 Michael H. Davis Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo
US4954636A (en) * 1989-07-03 1990-09-04 Gaf Chemicals Corporation Antimicrobial polymeric bisbiguanides
US5268168A (en) * 1990-02-19 1993-12-07 Sakai Engineering Co., Ltd. Antibacterial and deodorant processing agent and processing method using same
ZA952521B (en) * 1994-03-28 1996-03-15 Univ Columbia Composition for inactivating irritants in fluids
JPH08119878A (en) * 1994-10-19 1996-05-14 Lion Corp Antimicrobial agent and its production
GB9726132D0 (en) 1997-12-10 1998-02-11 Unilever Plc Deodorant composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075131A1 (en) * 2008-09-19 2010-03-25 Etzel Mark R Ligand Graft Functionalized Substrates
US20100075560A1 (en) * 2008-09-19 2010-03-25 Kannan Seshadri Ligand Graft Functionalized Substrates
US8551894B2 (en) * 2008-09-19 2013-10-08 3M Innovative Properties Company Ligand graft functionalized substrates
US9302208B2 (en) 2008-09-19 2016-04-05 3M Innovative Properties Company Ligand graft functionalized substrates
US9492771B2 (en) 2008-09-19 2016-11-15 3M Innovative Properties Company Ligand graft functionalized substrates
WO2011131773A1 (en) 2010-04-23 2011-10-27 Centre National De La Recherche Scientifique (C.N.R.S) Novel antimicrobial composition, use and preparation thereof
EP2386589A1 (en) * 2010-04-23 2011-11-16 Centre National de la Recherche Scientifique (C.N.R.S) Novel antimicrobial composition, use and preparation thereof

Also Published As

Publication number Publication date
JP2002510298A (en) 2002-04-02
CN100577142C (en) 2010-01-06
CA2295012A1 (en) 1998-12-17
ATE227932T1 (en) 2002-12-15
EP0987947A1 (en) 2000-03-29
DE69809548D1 (en) 2003-01-02
AU742600B2 (en) 2002-01-10
HUP0003065A3 (en) 2001-05-28
US6509022B2 (en) 2003-01-21
WO1998056253A1 (en) 1998-12-17
BR9810251A (en) 2000-09-19
GB9712317D0 (en) 1997-08-13
NZ501740A (en) 2002-02-01
JP2002505695A (en) 2002-02-19
EP0987946B1 (en) 2002-11-20
PL188771B1 (en) 2005-04-29
IN190655B (en) 2003-08-16
PL337277A1 (en) 2000-08-14
US20010006647A1 (en) 2001-07-05
CN1266350A (en) 2000-09-13
NO996042D0 (en) 1999-12-08
CN1259846A (en) 2000-07-12
AU7782598A (en) 1998-12-30
ZA985096B (en) 1999-01-12
AU7919298A (en) 1998-12-30
HUP0003065A2 (en) 2001-02-28
CA2293558A1 (en) 1998-12-17
DE69817564T2 (en) 2004-03-18
ES2205509T3 (en) 2004-05-01
BR9810435A (en) 2000-09-19
AR012965A1 (en) 2000-11-22
EP0987947B1 (en) 2003-08-27
JP4308331B2 (en) 2009-08-05
ZA985030B (en) 1999-12-10
NO996042L (en) 1999-12-08
AR015884A1 (en) 2001-05-30
KR20010013704A (en) 2001-02-26
DE69809548T2 (en) 2003-09-25
WO1998056252A1 (en) 1998-12-17
BR9810435B1 (en) 2009-08-11
RU2209620C2 (en) 2003-08-10
ID24652A (en) 2000-07-27
EP0987946A1 (en) 2000-03-29
DE69817564D1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
US20020142020A1 (en) Biocidal organic acid salts of a polymeric biguanide
JP3939355B2 (en) Synergistic fungicide composition containing ionene polymer and dodecylamine salt and method of use thereof
TW450786B (en) Solid biocidal compositions
US7008531B2 (en) Treatment of circulating water systems
AU2001292087B2 (en) Method and compositions
EP0593250A1 (en) Synergistic antimicrobial combination of polyether phosphonates and non-oxidizing biocides
JP5629905B2 (en) Industrial fungicide
AU8595198A (en) Composition for inhibiting microbial adhesion on surfaces
JPS5950642B2 (en) industrial disinfectant
PL201886B1 (en) Disinfectants
US5677345A (en) Synergistic antimicrobial composition of N- (dichlorofluoromethyl)thio!-N',N'-dimethyl-N-phenylsulfamide and alkylguanidine compounds
EP1110454A2 (en) 5-Carboxanilido-haloalkylthiazoles as antimicrobial and marine antifouling agents
EP0722658B1 (en) Storage stable biocide composition and process for making the same
US20030032768A1 (en) Double end-capped polymeric biguanides
CA2956308C (en) Synergistic antimicrobial composition
JPS6344121B2 (en)
US5663206A (en) Synergistic antimicrobial composition of N-decyl-N-isononyl-N,N-dimethyl ammonium chloride and alkylguanidine compounds
EP0771527A1 (en) Antimicrobial compounds with quick speed of kill
US5283264A (en) Chemically stable antimicrobial formulations of dimps
DE2952167A1 (en) NEW GUANIDINIUM COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MICROBIOCIDE AGENT
US6214885B1 (en) Use of polymers containing β-hydroxyalkylvinylamine units as biocides
JPH10139603A (en) Industrial antibacterial agent
CA2053162A1 (en) Admixtures of 2-bromo-2-bromomethylglutaronitrile and n,4-dihydroxy- -oxobenzene-ethanimidoyl chloride

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVECIA LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOOLLVEN, PETER;REEL/FRAME:010559/0117

Effective date: 19991109

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION